NXL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Nexalin advanced its pivotal HALO Clarity clinical trial toward Q2 2026 enrollmentApr 23, 2026
- Nexalin announces the pivotal HALO™ Clarity trial to support a planned De Novo FDA submission targeting the insomnia marketFeb 24, 2026
- Nexalin Technology completed FDA Q-Submission meeting for Gen-2 SYNC™ neurostimulation console in Alzheimer's disease programDec 3, 2025
- Nexalin Technology's Q-submission for Gen-2 SYNC accepted by U.S. FDA for treatment of Alzheimer's disease and dementiaNov 5, 2025
- Nexalin Technology announces additional positive clinical results in Alzheimer's disease with Gen-2 SYNC neurostimulation deviceOct 9, 2025